Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
TEMOVATE E
×
Overview
What is TEMOVATE E?
Temovate E (clobetasol propionate) Cream, 0.05% contains the active compound clobetasol propionate, a synthetic
corticosteroid, for topical use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight
degree of mineralocorticoid activity.
Chemically, clobetasol propionate is (11β,16β)-21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione,
and it has the following structural formula:
Clobetasol propionate has the molecular formula CHClFO and a molecular weight of 467. It is a white to cream-colored
crystalline powder insoluble in water.
Each gram of Temovate E contains 0.5 mg of clobetasol propionate in a white to off-white cream base consisting of
cetostearyl alcohol, isopropyl myristate, propylene glycol, cetomacrogol 1000, dimethicone 360, citric acid, sodium citrate,
purified water, and imidurea as a preservative.
What does TEMOVATE E look like?
What are the available doses of TEMOVATE E?
Cream: 0.05%
What should I talk to my health care provider before I take TEMOVATE E?
How should I use TEMOVATE E?
Temovate E is a super-high potency corticosteroid indicated for:
Apply a thin layer of Temovate E to the affected skin areas twice daily
and rub in gently and completely. Wash hands after each application.
Temovate E is a super-high potency topical corticosteroid; therefore,
In moderate to severe plaque-type psoriasis,
Temovate E applied to 5% to 10% of body surface area can be used for up to 4 weeks.
The total dosage should not exceed 50 grams per week.
When dosing for more than 2 weeks, any additional benefits
of extending treatment should be weighed against the risk of HPA suppression.
Therapy should be discontinued when control
has been achieved. If no improvement is seen within 2 weeks,
reassessment of diagnosis may be necessary.
Treatment beyond 4 consecutive weeks is not recommended.
Temovate E should not be used with occlusive dressings.
What interacts with TEMOVATE E?
Sorry No Records found
What are the warnings of TEMOVATE E?
Sorry No Records found
What are the precautions of TEMOVATE E?
Sorry No Records found
What are the side effects of TEMOVATE E?
Sorry No records found
What should I look out for while using TEMOVATE E?
None
What might happen if I take too much TEMOVATE E?
Topically applied Temovate E can be absorbed in sufficient amounts to produce systemic effects
[].
How should I store and handle TEMOVATE E?
Store at 20-25°C (68-77°F) [See
USP]. Protect from light.How Supplied®How Supplied®
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties.
The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are
thought to act by the induction of phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that
these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by
inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane
phospholipids by phospholipase A.
Non-Clinical Toxicology
None
Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic hypotension, dizziness, fatigue) may be induced or exacerbated.
Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction,
digitalis, calcium channel blockers, and beta-blockers. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil.
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (See
).
Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol. Causal relationship and relevance for clonidine oral tablets have not been established.
Clobetasol propionate is a highly potent topical corticosteroid that
has been shown to suppress the HPA axis at doses as low as 2 grams per day.
Systemic absorption of topical corticosteroids can produce reversible HPA axis
suppression with the potential for clinical glucocorticosteroid insufficiency.
This may occur during treatment or upon withdrawal of the topical corticosteroid.
Because of the potential for systemic absorption, use of topical corticosteroids may
require that patients be periodically evaluated for HPA axis suppression. In a study including
12 subjects ages 18 years and older with psoriasis or atopic dermatitis involving at least 30%
body surface area (BSA), adrenal suppression was identified in 3 out of 12 subjects (25%) following 1 week of treatment.
Factors that predispose a patient using a topical corticosteroid to HPA axis
suppression include the use of more potent steroids, use over large surface areas,
use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.
An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.
If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug,
to reduce the frequency of application, or to substitute a less potent steroid.
Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes
mellitus can also result from systemic absorption of topical corticosteroids.
Use of more than one corticosteroid-containing product at the same time may
increase the total systemic corticosteroid exposure.
Pediatric patients may be more susceptible to systemic toxicity
from use of topical corticosteroids. []
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
